In the US, it enjoyed sales of over US$116.1 million in Q1 2020 and US$117.7 million in Q2 2020. Existing pharmaceutical cannabis products will achieve growth rates of 150% between 2020 and 2024 to reach total value sales just shy of US$2 billion.

​